Abstract: A rotary wing aircraft includes a single main rotor hub configured to receive a rotor blade. The rotor blade includes a blade root, a blade tip, and a blade body. The blade body includes a leading edge and a trailing edge and defines a feathering axis. The leading edge and the trailing edge each include a first portion and a second portion that extend toward a first direction and a second portion, respectively. At a given radial location along the feathering axis, a local twist angle changes from a positive value to a negative value, a chord length decreases in value, a distance between the trailing edge and the feathering axis decreases in value, and the first portion of the leading edge extends toward the first direction. The rotor blade assembly also includes a trailing edge assembly having a trailing edge flap configured to be selectively deployed by an actuator.

Abstract: A method for stimulating or enhancing the immune system with a composition that includes a Eurycoma longifolia aqueous extract. Also provided is a method for reducing the risk of infectious disease by administering the composition. Further disclosed is a method for treating an individual with a Eurycoma longifolia aqueous extract to increase the number of T-cells, improve Scoring of Immunological Vigor, lower immunological age, reduce fatigue, or alleviate or reduce stress.

Abstract: The present invention is directed to a new kind of medicinal value or health care function of Eurycoma longifolia extracts, particularly in the treatment or alleviation symptoms and/or conditions associated to hormonal imbalance in females, including menopause and its related symptoms. In one aspect, the present invention discloses the use of a composition comprising a therapeutically effective amount of Eurycoma longifolia extract in the manufacture of a medicament for the alleviation of symptoms and/or conditions associated to hormonal imbalance in females, including menopause and its related symptoms. The alleviation of the symptoms and/or conditions according to the present invention is characterised by inducing a change in the hormonal contents of estrogen, progesterone, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Also disclosed is the use of a pharmaceutical composition comprising the therapeutically effective amount of Eurycoma longifolia extract.

Abstract: The present invention is directed to a new kind of medicinal value or health care function of Eurycoma longifolia extracts, particularly in the treatment or alleviation symptoms and/or conditions associated to hormonal imbalance in females, including menopause and its related symptoms. In one aspect, the present invention discloses the use of a composition comprising a therapeutically effective amount of Eurycoma longifolia extract in the manufacture of a medicament for the alleviation of symptoms and/or conditions associated to hormonal imbalance in females, including menopause and its related symptoms. The alleviation of the symptoms and/or conditions according to the present invention is characterised by inducing a change in the hormonal contents of estrogen, progesterone, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Also disclosed is the use of a pharmaceutical composition comprising the therapeutically effective amount of Eurycoma longifolia extract.

Abstract: A method for stimulating or enhancing the immune system with a composition that includes a Eurycoma longifolia aqueous extract. Also provided is a method for reducing the risk of infectious disease by administering the composition. Further disclosed is a method for treating an individual with a Eurycoma longifolia aqueous extract to increase the number of T-cells, improve Scoring of Immunological Vigor, lower immunological age, reduce fatigue, or alleviate or reduce stress.

Abstract: The present invention relates to a composition containing an extract from the Polygonum minus for cognition and cosmetic purposes. The extract of Polygonum minus includes quercetin-3-glucuronide and quercitrin. Extract of Polygonum minus is provided in an amount effective to reduce oxidative damage. A process for isolation of an active extract from Polygonum minus includes the steps of a) subjecting the Polygonum minus including aerial parts of the plant to solvent extraction preferably with a material solvent ratio of 1:10-20 by percolation at a temperature range of 70-105° C. preferably 80° C. to obtain the extract; and b) filtering the extract obtained from step (a) followed by concentration and drying involving freeze drying, spray drying or vacuum belt drying to obtain therefrom the dry extract powder.

Abstract: Services and applications running on devices placed in live wireless environments are tested and reported to determine the relative performance of the device under test. Multiple logs collected from the device under test are combined and transmitted to a remote backend system. The backend system stores and analyzes the combined logs to generate reports containing factual and relative performance information regarding the device during the testing period. The nature of the test, the collected log information, and the report format may all be modified according to the criteria of the requestor.

Abstract: Method for producing an extract or extract formulation of the fruit of Canarium odontophyllum comprising or consisting of the following steps: (i) providing fruit material from Canarium odontophyllum, wherein said fruit material essentially consists of the endocarp of the seeds of Canarium odontophyllum, (i-a) optionally drying the fruit material provided in step (i), (ii) extracting the fruit material provided in step (i) or (i-a) with a mixture essentially consisting or consisting of water and an alcohol having 1 to 3 carbon atoms or consisting water and acetonitrile, (iii) optionally partially or fully removing the alcohol having 1 to 3 carbon atoms of step (ii), and optionally adding an organic solvent of medium polarity to said aqueous residue and extracting the aqueous residue with said organic solvent or a supercritical solvent, such as supercritical carbon dioxide thereby obtaining an enriched extract, (iv) optionally mixing the extract obtained in step (ii) or the enriched extract obtained in

Abstract: The present invention discloses the use of a composition comprising an effective amount of an extract of Eurycoma longifolia for the production of a preparation to stimulate and/or enhance the immune system. In a preferred embodiment, the extract comprises active ingredients, which include eurycomanone, protein, polysaccharide and glycosaponin in appropriate amounts. In another preferred embodiment, the extract has an activity selected from the group consisting of: increasing the number of T-cells; improving Scoring of Immunological Vigor (SIV), a comprehensive index of overall immune function; lowering the immunological age, a comprehensible form of immune function based on T-cell number and proliferative activity; reducing fatigue; and alleviating or reducing stress. Also disclosed is a method of for treating an individual to achieve an outcome selected from the group consisting of increasing the number of T-cells, improving SIV (i.e.

Abstract: The present invention relates to a composition containing an extract from the Polygonum minus for cognition and cosmetic purposes. The extract of Polygonum minus includes quercetin-3-glucuronide and quercitrin. Extract of Polygonum minus is provided in an amount effective to reduce oxidative damage. A process for isolation of an active extract from Polygonum minus includes the steps of a) subjecting the Polygonum minus including aerial parts of the plant to solvent extraction preferably with a material solvent ratio of 1:10-20 by percolation at a temperature range of 70-105° C. preferably 80° C. to obtain the extract; and b) filtering the extract obtained from step (a) followed by concentration and drying involving freeze drying, spray drying or vacuum belt drying to obtain therefrom the dry extract powder.

Abstract: The use or methods of use of extracts comprising one or more special clerodane compounds against inflammatory (including allergic) diseases or conditions, as well as novel compounds of this type, said clerodane derivatives for use against inflammatory (including allergic) diseases or conditions, pharmaceutical formulations comprising them especially for use against inflammatory disease or conditions, and related embodiments; said extract and/or compound(s) for use in the treatment or in the preparation of a medicament (including a nutraceutical) for the prophylactic and/or therapeutic treatment of said disease or condition, as well as their preparation; pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in said prophylactic and/or therapeutic treatment, and related embodiments.

Abstract: The present invention primarily relates to the use of certain extract formulations of Rhodamnia cinerea as defined herein as alpha-amylase inhibitors and as actives for the therapeutic (including prophylactic) treatment of a carbohydrate metabolic disorder or of a disease attendant on hyperglycemia, preferably selected from the group consisting of prediabetes, obesity, hyperlipemia, arteriosclerosis, arteriolosclerosis, atherosclerosis, diabetes, postprandial hyperglycemia, and metabolic syndrome. The present invention also relates to corresponding methods. The invention further relates to specific extract formulations obtainable from Rhodamnia cinerea and to compositions, in particular orally consumable compositions, comprising an effective amount of such an extract formulation.

Abstract: Services and applications running on devices placed in live wireless environments are tested and reported to determine the relative performance of the device under test. Multiple logs collected from the device under test are combined and transmitted to a remote backend system. The backend system stores and analyzes the combined logs to generate reports containing factual and relative performance information regarding the device during the testing period. The nature of the test, the collected log information, and the report format may all be modified according to the criteria of the requestor.

Abstract: Seven novel antibiotic substances can be produced by cultivation of a microbial strain which has been isolated from a soil sample and which is designated as Microbispora sp. A 34030 (deposited under an access number FERM BP-10505 in terms of Budapest Treaty). These seven antibiotic substances are named as bispolide A1, bispolide A2, bispolide A3, bispolide B1, bispolide B2a, bispolide B2b and bispolide B3, respectively. These bispolides are each novel compounds which have a chemical structure as collectively represented by the general formula (III) shown below: These bispolides have each a high antibacterial activity against a variety of bacteria, particularly Gram-positive bacteria and their antibiotic-resistant strains, and hence these bispolides each are effective and useful for therapeutically treating bacterial infections of Gram-positive bacteria in humans and animals.

Abstract: The use or methods of use of extracts comprising one or more special clerodane compounds against inflammatory (including allergic) diseases or conditions, as well as novel compounds of this type, said clerodane derivatives for use against inflammatory (including allergic) diseases or conditions, pharmaceutical formulations comprising them especially for use against inflammatory disease or conditions, and related embodiments; said extract and/or compound(s) for use in the treatment or in the preparation of a medicament (including a nutraceutical) for the prophylactic and/or therapeutic treatment of said disease or condition, as well as their preparation; pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in said prophylactic and/or therapeutic treatment, and related embodiments.

Abstract: The invention relates to aurones and extracts comprising them useful in the prophylactic and/or therapeutic treatment of an animal (including a human) with an estrogen receptor (ER) related disease or condition of the animal or human body, as well as methods, uses and other inventions related thereto.

Abstract: The invention relates to aurones and extracts comprising them useful in the prophylactic and/or therapeutic treatment of an animal (including a human) with a phosphodiesterase (PDE) dependent disease or condition of the central nervous system, as well as methods, uses and other inventions related thereto.

Abstract: Seven novel antibiotic substances could be produced by cultivation of a microbial strain which has been isolated from a soil sample and which is designated as Microbispora sp. A 34030 (deposited under an access number FERM BP-10505 in terms of Budapest Treaty). These seven antibiotic substances are named as bispolide A1, bispolide A2, bispolide A3, bispolide B1, bispolide B2a, bispolide B2b and bispolide B3, respectively. These bispolides are each novel compounds which have a chemical structure as collectively represented by the general formula (III) shown below. These bispolides have each a high antibacterial activity against a variety of bacteria, particularly Gram-positive bacteria and their antibiotic-resistant strains, and hence these bispolides each are effective and useful for therapeutically treating bacterial infections of Gram-positive bacteria in human and animals.